Co-Diagnostics, Inc. (CODX) Dividend History

Co-Diagnostics, Inc. (CODX) is a molecular diagnostics company specializing in the development and commercialization of innovative, cost-effective diagnostic tests. The company is known for its proprietary technology platform, Logix, which enables rapid design and production of PCR-based tests for infectious diseases, including COVID-19. Co-Diagnostics focuses on providing reliable diagnostic solutions for healthcare, agriculture, and animal health markets worldwide.

4049 South Highland Drive, Salt Lake City, UT, 84124
Phone: (801) 278-9769
Website: https://www.codiagnostics.com

Dividend History

Co-Diagnostics, Inc. currently does not pay dividends

Company News

Infectious Disease Diagnostics Market to Reach USD 43.09 Billion by 2031 | SkyQuest Technology

The global infectious disease diagnostics market is projected to reach $43.09 billion by 2031, growing at a CAGR of 8.20% during the forecast period. The market is driven by advancements in diagnostic technologies, rising cases of infectious diseases, and increased R&D funding.

Benzinga

Featured Companies: ABT BDX BIO BIO.B DHR OSUR QDEL QGEN RVTY TMO
Elevance Health (ELV) Beats Q1 Earnings Estimates

Elevance Health (ELV) delivered earnings and revenue surprises of 0.95% and 0.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research

Featured Companies: ELV
Why Co-Diagnostics Stock Slipped Today

Investors continued to avoid the company after its big second-quarter whiffs.

The Motley Fool
Why Co-Diagnostics Is A Solid Covid-19 Play

Co-Diagnostics shares rallied after the company posted strong Q2 earnings. TAM is expanding and the stock CODX is trading at too low a market capitalization in the $300M range.

Seeking Alpha

Featured Companies: ENLV JNJ MRNA NVAX PFE REGN

Page data last updated 07/23/2025 14:41:06 UTC